Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.…
Dermata Announces U.S. Trademark Registration for TOME(R)
Dermata Therapeutics (NASDAQ: DRMA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.5095 USD on 20 November 2026, down 83.2% over 52 weeks. Its 52-week range is 0.5004 USD to 4.660 USD: the price is 89.1% below the high and 1.8% above the low.
Its market capitalisation is 2.51M USD.
Dermata Therapeutics reports return on equity of -121.5%.
It holds more cash than debt, a net cash position of 4.82M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 2.000 USD is 292.5% above the current price.